• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

tetano

Editor, Senior Moderator
Vaccine. 2014 Sep 17. pii: S0264-410X(14)01247-X. doi: 10.1016/j.vaccine.2014.08.079. [Epub ahead of print]
Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines.
Ward BJ1, Landry N2, Tr?panier S3, Mercier G4, Dargis M5, Couture M6, D'Aoust MA7, V?zina LP8.
Author information
Abstract
BACKGROUND:

Plant-made biotherapeutics are gathering momentum and some plant glycoproteins are allergens. Glycans with core β1-2xylose and α1,3fucose motifs and antennae terminated by mannose residues (e.g.: MMXF) are found on several plant allergens and can cross-react with glyco-epitopes from other sources. To date, reactivity to these cross-reactive determinants has not been associated with clinical symptoms.
OBJECTIVE:

We produced VLP vaccines bearing the hemagglutinin(HA) of H5(A/Indonesia/5/05) or H1(A/California/07/09) influenza viruses by transfection of Nicotiana benthamiana. Subjects enrolled in Phase I/II trials were followed for evidence of allergy/hypersensitivity and development of antibodies against plant glyco-epitopes.
METHODS:

A total of 280/349 subjects received either one (H1) or 2 doses (H5) of vaccine (5-45μg of HA/dose) intramuscularly including 40 with pre-existing plant allergies. Subjects were monitored for 6 months. IgG and IgE to plant glyco-epitopes were measured by ELISA using corn-/egg-derived avidin and bromelain as target antigens.
RESULTS:

No subject developed allergic/hypersensitivity symptoms. Some (34%) developed transient IgG and, in some cases IgE, to plant glyco-epitopes but no subject mounted an IgE response to the MMXF motif. Antibodies returned to baseline by 6 months in most subjects.
CONCLUSION:

VLP vaccines bearing influenza HA glycoproteins can elicit transient IgG and, in some cases, IgE responses that are not associated with either the development or worsening of allergic/hypersensitivity symptoms.

Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:

Allergy; Bromelain assay; CCDs; Cross-reactive carbohydrate determinants; Humoral response; IgE; IgG; Influenza A virus; Plant-made vaccines; Plant-specific glycans

PMID:
25240757
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25240757
 
Back
Top Bottom